biostudies-literatureRosenblat TLNCI NIH HHSNIHLymphoma Foundation, and Actinium Pharmaceuticals, Inc.2030-2037https://www.ebi.ac.uk/biostudies/studies/S-EPMC9106874biostudies-literatureUnknown28(10)<h4>Purpose</h4>The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML). To increase its potency, lintuzumab was conjugated to actinium-225 (225Ac), a radionuclide yielding 4 α-particles. This first-in-human, phase I trial was conducted to determine the safety, pharmacology, and biological activity of 225Ac-lintuzumab.<h4>Patients and methods</h4>Eighteen patients (median age, 64 years; range, 45-80) with relapsed or refractory AML received a single infusion of 225Ac-lintuzumab at activities of 18.5 to 148 kBq/kg.<h4>Results</h4>The maximum tolerated dose was 111 kBq/kg. Dose-limiting toxicities included myelosuppression lasting > 35 days in one patient receiving 148 kBq/kg and death from sepsis in two patients treated with 111 and 148 kBq/kg. MyelosuppreClinical cancer research : an official journal of the American Association for Cancer ResearchTreatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.PMC9106874RO1 55349P30 CA008748P01 CA033049R01 CA055349PO1 CA33049R35 CA241894Carrasquillo JALarson SMMcDevitt MRPark JHRosenblat TLScheinberg DAMaslak PGPandit-Taskar NDouer DCicic DFrattini MGJurcic JGfalseTreatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.<h4>Purpose</h4>The anti-CD33 antibody lintuzumab has modest activity against acute myeloid leukemia (AML). To increase its potency, lintuzumab was conjugated to actinium-225 (225Ac), a radionuclide yielding 4 α-particles. This first-in-human, phase I trial was conducted to determine the safety, pharmacology, and biological activity of 225Ac-lintuzumab.<h4>Patients and methods</h4>Eighteen patients (median age, 64 years; range, 45-80) with relapsed or refractory AML received a single infusion of 225Ac-lintuzumab at activities of 18.5 to 148 kBq/kg.<h4>Results</h4>The maximum tolerated dose was 111 kBq/kg. Dose-limiting toxicities included myelosuppression lasting > 35 days in one patient receiving 148 kBq/kg and death from sepsis in two patients treated with 111 and 148 kBq/kg. Myelosuppre2022-01-01T00:00:00Z2022 May2025-05-29T16:11:45.459Z2025-04-04T09:32:15.775ZS-EPMC91068743524791510.1158/1078-0432.ccr-21-371210.1158/1078-0432.CCR-21-3712